Caduceus Software Systems Corp. (OTCBB: CSOC) reached up 44.44% in morning trading to $.039 with 2M shares traded. Caduceus Software Systems Corp. is a software company that specializes in developing an all-in-one solution for private practitioners and doctors. They are in the healthcare information management industry. They are headquartered in the United Kingdom, specifically located in the metropolitan city of Birmingham. Caduceus Software Systems Corp. (OTCBB: CSOC - News) announced that it will introduce a revolutionary mapping tool to its Caduceus MMS software core.
MMRGlobal, Inc. (OTCBB: MMRF) reached up 28.21% in morning trading to $.05 with 800K shares traded. MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MMRGlobal, Inc. (OTC.BB: MMRF.OB - News) ("MMR"), today announced it has received a proposed agreement from Surgery Center Management, LLC to license certain of the Company's Health Information Technology and Personal Health Record patents for a minimum license fee of $30 million plus additional royalties on terms to be negotiated.
PolyMedix, Inc. (OTCBB:PYMX) reached up 19.86% in morning trading to $.70 with 1M shares traded. PolyMedix is a clinical stage biotechnology company that is developing first-in-class, small-molecule drugs for the treatment of serious acute care conditions. Using their proprietary drug discovery platform, they have internally created a pipeline of innovative infectious disease and cardiovascular products that meet the following criteria: • Address large market opportunities • Therapeutic areas with efficient, inexpensive development paths • Clear clinical endpoints • Early clinical proof of concept. PolyMedix, Inc. (OTCBB:PYMX.OB - News) announced that an interim analysis of results from more than 80 patients enrolled in its Phase 2 clinical trial with PMX-30063 defensin-mimetic antibiotic, indicate that all dosing arms in the study were both safe and effective in treating patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by S. aureus. This is the first ever patient clinical efficacy study conducted with this new defensin-mimetic antibiotic class. PolyMedix is continuing to enroll patients and expects to complete the full trial in the first half of 2012.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
